2 completed, 2 recruiting, 1 enrolling by invitation, 1 terminated. 4 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 1, Enrolling by invitation 1, Recruiting 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Enrolling by invitation 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow C1 Inhibitor Deficiency: new trials by email Literature Review of C1 Inhibitor Deficiency trials Research Report on C1 Inhibitor Deficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients Deucrictibant XR tablet, Placebo comparator to XR tablet, Deucrictibant 20 mg capsule - Hereditary Angioedema (HAE), Angioedema | Phase 1 / Phase 2 | Recruiting | Institute for Asthma and Allergy | 10 | 2025-03-10 | 2025-07-02 |
| Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Deucrictibant, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 3 | Completed | Pharvaris Netherlands B.V. | 134 | 2024-02-26 | 2025-11-21 |
| Angioedema Biomarker Research Study Venipuncture - Angioedema, Angioedemas, Hereditary | Recruiting | Foundation For Rare Disease Research | 600 | 2024-01-15 | 2026-08-24 | |
| Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema deucrictibant - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 / Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 150 | 2022-12-28 | 2026-07-21 |
| Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II Deucrictibant low dose, Deucrictibant high dose, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 | Terminated | Pharvaris Netherlands B.V. | 34 | 2022-04-19 | 2026-08-17 |
| Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Deucrictibant, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 | Completed | Pharvaris Netherlands B.V. | 74 | 2021-02-03 | 2025-12-17 |
Angioedemas, Hereditary (6) · Hereditary Angioedema Types I and II (4) · Angioedema (2) · Hereditary Angioedema Type III (2) · Mastocytosis (1) · Mastocytosis, Systemic (1) · Urticaria (1)
Cardiovascular Diseases (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Hereditary Complement Deficiency Diseases (6) · Hypersensitivity (6) · Hypersensitivity, Immediate (6) · Immune System Diseases (6) · Immunologic Deficiency Syndromes (6) · Primary Immunodeficiency Diseases (6) · Skin Diseases (6) · Skin Diseases, Vascular (6) · Skin and Connective Tissue Diseases (6) · Vascular Diseases (6) · Urticaria (5) · Angioedema (4)
Phlebotomy (1)
Pharvaris Netherlands B.V. (4) · Foundation For Rare Disease Research (1) · Institute for Asthma and Allergy (1)
United States (6) · Bulgaria (4) · Canada (4) · Germany (4) · Italy (4) · Poland (4) · United Kingdom (4) · Austria (3) · Czechia (3) · France (3) · Hungary (3) · Netherlands (3) · Spain (3) · Argentina (2) · Australia (2)
Lili Wan, PhD (1) · Marc Riedl, MD (1) · Marcus Maurer, Prof MD (1)
PMID 41865746, PMID 41865747, PMID 42849489
2023 (1)